GPCR — Structure Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $1.36bn
- $477.80m
- 44
- 34
- 13
- 20
Annual cashflow statement for Structure Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -15.9 | -38 | -51.3 | -89.6 | -123 |
| Depreciation | |||||
| Non-Cash Items | 0.647 | 1.75 | 1.96 | 2.87 | 1.93 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.946 | 4.06 | 2.97 | 6.97 | 2.96 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -14.3 | -32.2 | -46.1 | -79.5 | -117 |
| Capital Expenditures | -0.019 | -1.21 | -0.155 | -2.17 | -1.29 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -21.1 | 19.1 | -62 | -266 | -358 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -21.1 | 17.9 | -62.1 | -268 | -359 |
| Financing Cash Flow Items | 0 | -0.115 | -2.52 | -21.6 | -1.8 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 25.8 | 103 | 29 | 452 | 515 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -9.59 | 89 | -79.2 | 104 | 39.7 |